Stocktoria
Zentalis Pharmaceuticals, Inc. ZNTL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-04-03
Zentalis Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $67.4M | $0 | $0 | — |
| R&D expense | $107.3M | $167.8M | $189.6M | $172.7M | $175.6M |
| Operating income | -$152.8M | -$191.2M | -$299.5M | -$227.3M | -$216.5M |
| Income tax | $442,000 | $177,000 | -$601,000 | -$469,000 | -$297,000 |
| Net income | -$137.1M | -$165.8M | -$292.2M | -$236.8M | -$158.7M |
| EPS (diluted) | $-1.91 | $-2.33 | $-4.47 | $-4.48 | $-3.72 |
| Operating cash flow | -$125.2M | -$170.9M | -$207.8M | -$163.8M | -$154.1M |
| Free cash flow | -$125.2M | -$171.1M | -$208.4M | -$166.3M | -$160.2M |
| Cash & equivalents | $36.0M | $33.9M | $28.0M | $43.1M | $59.7M |
| Total assets | $289.0M | $430.3M | $551.7M | $539.3M | $454.5M |
| Total liabilities | $72.8M | $93.2M | $114.3M | $105.3M | $90.0M |
| Shareholders' equity | $216.2M | $337.2M | $437.4M | $434.0M | $364.5M |
Source: SEC EDGAR filings · CIK 0001725160 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.